Peptide Half-Life & Bioavailability Explained

What Is Half-Life and Why It Determines Dosing Frequency

The plasma half-life (t½) of a peptide is the time required for its concentration in blood plasma to reduce by 50% following administration. After one half-life, 50% remains; after two, 25%; after five half-lives, less than 3.2% of the original dose remains — at which point the compound is considered effectively cleared. The practical importance of half-life for research design is direct: it determines how long the compound maintains biologically effective concentrations at its target receptor, and therefore governs appropriate dosing frequency.

A peptide with a 20-minute half-life (e.g., native GHRH, Sermorelin) must be administered more frequently to maintain sustained receptor activation than one with a 2-hour half-life (e.g., Ipamorelin) or a 6-day half-life (e.g., CJC-1295 with DAC). Misunderstanding a compound's half-life leads to either under-dosing frequency (producing sub-therapeutic receptor exposure) or over-dosing frequency (accumulation and receptor desensitisation).

Bioavailability by Administration Route

Bioavailability (F) is the fraction of an administered dose that reaches systemic circulation in active form. For intravenous administration, bioavailability is by definition 100% — the entire dose enters circulation directly. For other routes, absorption barriers, first-pass metabolism, and local degradation reduce the fraction reaching circulation. Route selection profoundly affects both bioavailability and the pharmacokinetic profile.

Route

Bioavailability (approx.)

Onset

Research Notes

Intravenous (IV)

100%

Seconds

Reference standard. Immediate Cmax. Used in PK studies and acute signalling research. Requires sterile preparation and controlled infusion rate.

Subcutaneous (SC)

75–95% (most peptides)

15–45 min to Cmax

Standard for most research peptide protocols. Slower absorption depot effect. Comparable bioavailability to IV for many peptides. Practical and minimally invasive.

Intramuscular (IM)

80–95%

10–30 min to Cmax

Slightly faster than SC for some compounds. Useful when SC depot formation is undesirable. More painful; less commonly used for peptide research.

Intranasal

5–40% (highly variable)

5–20 min to Cmax

Bypasses first-pass. Brain penetration for small peptides (e.g., Semax, Selank). Bioavailability variable depending on molecular size, mucosal absorption, mucociliary clearance. Only practical for small peptides (<5 kDa).

Oral

<1–5% (most peptides)

30–90 min

Peptide bonds cleaved by GI proteases. Practically negligible bioavailability for most research peptides. Exception: BPC-157 (documented oral activity in rodents). Requires special formulation strategies (nanoparticles, cyclodextrins) for meaningful systemic bioavailability.

Topical / Transdermal

1–15% (small peptides only)

Hours

Stratum corneum barrier limits penetration to small (<1 kDa), lipophilic peptides. GHK-Cu in cosmetic applications. Larger peptides require penetration enhancers or microneedle delivery for meaningful absorption.

Why Most Peptides Cannot Be Taken Orally

The gastrointestinal tract is an efficient peptide destruction system — evolutionarily optimised to break dietary proteins and peptides into absorbable amino acids. Multiple peptidase enzymes in the stomach (pepsin), pancreas (trypsin, chymotrypsin, elastase), and intestinal brush border (aminopeptidases, carboxypeptidases, dipeptidyl peptidases) cleave peptide bonds at different sequence preferences with high efficiency. A research peptide swallowed as a capsule or dissolved in liquid encounters this full gastrointestinal proteolytic arsenal before any possible absorption.

For most peptides longer than 3–5 amino acids, oral bioavailability is negligible — below 1% reaching systemic circulation. This is not a formulation problem that better pill design can solve; it is a fundamental biochemical reality. The exceptions are genuinely unusual: BPC-157's gastric acid stability stems from its specific proline-rich sequence, and very small peptides (dipeptides, tripeptides) can exploit intestinal peptide transporters (PEPT1/PEPT2) for partial absorption.

Peptide Degradation Pathways in Plasma

DPP-IV: The Primary Peptide Protease

Dipeptidyl peptidase IV (DPP-IV) is a serine protease expressed on endothelial cells throughout the vascular system that cleaves dipeptides from the N-terminus of peptides with proline or alanine at position 2. This enzyme is responsible for the extremely short half-life of native GHRH (t½ ~5 minutes) — it cleaves the Tyr-Ala bond at positions 1–2, inactivating the peptide. The DPP-IV resistance modifications introduced in Sermorelin, Mod GRF 1-29, and CJC-1295 (substituting Ala at position 2 with more DPP-IV–resistant amino acids) directly address this degradation pathway and account for their extended half-lives.

DPP-IV inhibition (e.g., by pharmaceutical sitagliptin or naturally by the flavonoid luteolin) is a potential confounding variable in GH axis peptide research — researchers using animals receiving DPP-IV inhibitors will observe markedly extended peptide half-lives compared to controls.

Neutral Endopeptidase (NEP/Neprilysin) and ACE

Neutral endopeptidase (NEP, also called neprilysin or CD10) cleaves peptide bonds on the N-terminal side of hydrophobic amino acids and is responsible for rapid inactivation of many bioactive peptides including enkephalins, substance P, and natriuretic peptides. Angiotensin-converting enzyme (ACE) cleaves C-terminal dipeptides and is important for the inactivation of vasoactive peptides. Both enzymes are expressed on vascular endothelium and contribute to the rapid clearance of many research peptides.

Renal Filtration

Peptides below approximately 30–50 kDa are freely filtered by the renal glomerulus and rapidly cleared from plasma. Smaller peptides (under 5 kDa, as most research peptides are) undergo glomerular filtration and proximal tubular catabolism — an additional clearance route that contributes to their short plasma half-lives. This is why molecular weight–based half-life extension strategies (PEGylation, albumin binding) work: they increase apparent molecular weight above the renal filtration threshold.

Structural Strategies for Half-Life Extension

#### D-Amino Acid Substitution

Replacing L-amino acids with their D-enantiomers at protease cleavage sites confers resistance to stereospecific proteases without eliminating receptor binding. Used in: Ipamorelin (D-2-Nal, D-Phe), GHRP-2 (D-2-Nal, D-Ala), SS-31 (D-Arg, D-Phe). Increases half-life 2–10× depending on position and compound.

#### N/C-Terminal Modifications

N-terminal acetylation and C-terminal amidation protect the termini from exopeptidase attack (aminopeptidases and carboxypeptidases). C-terminal amidation (-NH₂ instead of -COOH) is present in most modern research peptides. Provides modest half-life extension of 1.5–3×.

#### Albumin Binding (DAC Technology)

Covalent or non-covalent binding to serum albumin (t½ ~19 days) dramatically extends half-life. CJC-1295 with DAC uses an MPA linker for covalent albumin binding — transforming a 30-minute peptide into one with a 6–8 day half-life. Non-covalent albumin binders (fatty acid conjugates) used in pharmaceutical GLP-1 analogues (semaglutide).

#### Cyclic Peptide Structure

Cyclisation via lactam bridges, disulfide bonds, or head-to-tail cyclisation increases rigidity and resistance to proteolytic cleavage by conformationally restricting protease access. Used in: Bremelanotide/PT-141 (cyclic heptapeptide), MT-II (cyclic). Typically extends half-life 3–10× over linear parent sequence.

#### Non-Natural Amino Acid Incorporation

Incorporating non-proteinogenic amino acids (Aib/α-aminoisobutyric acid, β-amino acids, N-methyl amino acids) at DPP-IV or other protease cleavage sites confers resistance without D-amino acid isomerisation. Used in Ipamorelin (Aib at position 1). Provides selective protease resistance.

#### PEGylation

Covalent attachment of polyethylene glycol (PEG) chains dramatically increases hydrodynamic radius, reducing renal filtration and slowing receptor association kinetics. Commonly used in therapeutic proteins (pegylated interferons, pegfilgrastim). Less common in small research peptides due to antigenicity concerns and activity reduction.

Reference Half-Life Data for Common Research Peptides

Compound

Plasma Half-life

Biological Window

Primary Degradation Route

Native GHRH(1–44)

~5 minutes

~15–30 min

DPP-IV (N-terminal cleavage)

Sermorelin / GRF(1–29)

~10–20 minutes

~30–60 min

DPP-IV; non-specific proteases

Mod GRF 1-29 (CJC-1295 no DAC)

~30 minutes

~2–3 hours

Non-specific proteases (DPP-IV resistant)

CJC-1295 with DAC

~6–8 days

~14 days

Albumin recycling; eventual renal clearance

Tesamorelin

~26–38 minutes

~2–3 hours

Non-specific proteases (DPP-IV partially resistant)

Ipamorelin

~2 hours

~3–4 hours

Non-specific peptidases; renal

GHRP-2

~15–60 minutes

~2 hours

Non-specific peptidases; renal

GHRP-6

~15–60 minutes

~2 hours

Non-specific peptidases; renal

BPC-157

~4 hours (estimated)

~6–8 hours

Renal; slow protease degradation

IGF-1 LR3

~20–30 hours

~36–48 hours

Receptor-mediated endocytosis; renal

Semax

~20 minutes

~4–6 hours (intranasal; CNS retention)

Peptidases; renal

Epithalon

Not well characterised

Cellular effects persist beyond plasma half-life

Renal; peptidases

Protocol Design Implication

A peptide's plasma half-life and its duration of biological effect are not always equivalent. SS-31 has a plasma half-life of ~2–3 hours but concentrates in mitochondria where its effective residence time is substantially longer. Semax has a short plasma half-life but demonstrates CNS effects lasting several hours, attributed to retention in CNS tissue after intranasal delivery. Always consider the target compartment's kinetics, not just plasma half-life, when determining research dosing intervals.

Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Pharmacokinetic data cited represents published literature values that may vary with species, dose, route, and analytical methodology. This content does not constitute medical advice. Researchers must comply with all applicable institutional and jurisdictional regulations.